Sign In
Buy IBIO
$1.84
+0.0800 (+4.55%)
At Close: Jun 03, 2026
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
02:35pm, Friday, 05'th Apr 2024
The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in
iBio stock nearly tripled on Wednesday: here's why
02:43pm, Wednesday, 27'th Mar 2024
Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.
iBio partners with AstralBio to develop obesity treatments using AI-driven platform
11:54am, Wednesday, 27'th Mar 2024
iBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop n
Why Is iBio (IBIO) Stock Up 125% Today?
10:04am, Wednesday, 27'th Mar 2024
iBio‘s (NYSEMKT: IBIO ) shares are trending, and IBIO stock is up 125% today after the firm used two of the market's favorite buzzwords — artificial intelligence (AI) and obesity drugs — in a pr
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –
iBio Announces $15.0 Million Private Placement
07:35pm, Tuesday, 26'th Mar 2024
– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
07:45am, Monday, 26'th Feb 2024
– Deal includes $1 million upfront and potential future milestone payments – – iBio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates –
iBio Announces Participation in 23rd Annual PepTalk Conference
08:15am, Tuesday, 16'th Jan 2024
- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning - - VP of Platform Technologies, Matt Gr
iBio Amends and Extends Maturity of Credit Agreement
07:15am, Tuesday, 26'th Dec 2023
– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, I
Why Is iBio (IBIO) Stock Down 41% Today?
08:48am, Tuesday, 05'th Dec 2023
Ibio (NYSEMKT: IBIO ) stock is falling hard on Tuesday after the biotechnology company announced the pricing of a public share offering. That offering has the company selling 2.25 million shares of IB
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
08:00am, Tuesday, 05'th Dec 2023
BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2
iBio Announces Reverse Stock Split
05:20pm, Monday, 27'th Nov 2023
BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split
- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action -
iBio Explains Recent Filing of Registration Statement
06:45am, Monday, 02'nd Oct 2023
– No new securities are being registered under the Post-Effective Amendment – – No new securities are being registered under the Post-Effective Amendment –
Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done
04:06pm, Thursday, 28'th Sep 2023
The healthcare industry has historically provided significant returns to investors. And, it is currently boasting a compounding annual growth rate prediction of 10.4% until 2027.
